Drug intelligence / Profile preview

COVac32020

Development stage: Preclinical
Lead developer: Celprogen
Modality: Peptides, Vaccines & Immunotherapeutics

Overview

COVac32020 (also known as COVID Vaccine 32020) is a vaccine candidate developed by Celprogen for the prevention of COVID-19 (SARS-CoV-2 infection). The vaccine is produced using Celprogen's proprietary stem cell platform combined with synthetic viral peptides. It is designed to elicit a protective immune response against the SARS-CoV-2 virus. As of the latest reports, the candidate has demonstrated potential in pre-clinical studies, though specific details regarding the target antigens or clinical trial phases are limited.

Other names: COVID-Vaccine 32020-Celprogen-vaccine-COVID-19-SARS-CoV-2 infectionCOVID-Vaccine32020-Celprogen-vaccine-COVID-19-SARS-CoV-2 infectionCOVID-Vaccine-32020-Celprogen-vaccine-COVID-19-SARS-CoV-2 infection

Beyond the preview

Go deeper on COVac32020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVac32020.

Explore the full profile